Loading clinical trials...

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination

NCT04930770•Maria Joyera Rodríguez

View on ClinicalTrials.gov

Summary

The objective will be to analyze the development of cellular and humoral immunity against SARS-CoV-2 after administration of a third dose of mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full standard (two-dose) regimen.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age \> 18 years;
•2. Male or female sex;
•3. Renal transplant with stable renal function in the last 2 months prior to study inclusion.
•4. Had received a full schedule of vaccination for SARS-CoV-2 with mRNA1273 vaccine (Moderna) and remained seronegative at 2 weeks after the second dose.
•5. Patient giving written informed consent.

Exclusion Criteria

•1. Renal transplantation \< 3 months;
•2. Pregnancy or lactation status;
•3. Rejection treated within the last 6 months;
•4. Presence of humoral immunity to SARS-CoV-2 defined as the presence of specific IgM/IgG.

Key Dates

Start Date

September 1, 2021

Primary Completion Date

December 1, 2021

Completion Date

March 1, 2022

Last Updated

June 22, 2025

Conditions

Covid19

Interventions

MRNA-1273

DRUG

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy